Effect of Statins on Intracerebral Hemorrhage
Outcome and Recurrence

Emilie FitzMaurice, AB; Lauren Wendell, MS; Ryan Snider, AB; Kristin Schwab, BA; Rishi Chanderraj, BS; Cathrine Kinnecom, MS, RN; Kaveer Nandigam, MD; Natalia S. Rost, MD; Anand Viswanathan, MD, PhD; Jonathan Rosand, MD, MS; Steven M. Greenberg, MD, PhD; Eric E. Smith, MD, MPH, FRCPC

Background and Purpose—3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, have been associated with improved outcome after ischemic stroke and subarachnoid hemorrhage but an increased risk of incident intracerebral hemorrhage (ICH). We investigated (1) whether statin use before ICH was associated with functional independence at 90 days, and (2) whether survivors exposed to statins after ICH had an increased risk of recurrence.

Methods—We analyzed 629 consecutive ICH patients with 90-day outcome data enrolled in a prospective cohort study between 1998 to 2005. Statin use was determined by patient interview at the time of ICH and supplemented by medical record review. Independent status was defined as Glasgow Outcome Scale 4 or 5. ICH survivors were followed by telephone interview every 6 months.

Results—Statin use were used by 149/629 (24%) before ICH. There was no effect of pre-ICH statin use on the rates of functional independence (28% versus 29%, $P=0.84$) or mortality (46% versus 45%, $P=0.93$). Medical comorbidities and warfarin use were more common in statin users. Hematoma volumes were similar (median 28 cm$^3$ in pre-ICH statin users compared to 22 cm$^3$ in nonusers, $P=0.18$). The multivariable-adjusted odds ratio for independent status in pre-ICH statin users was 1.16 (95% CI 0.65 to 2.10, $P=0.62$). ICH survivors treated with statins after discharge did not have a higher risk of recurrence (adjusted HR 0.82, 95% CI 0.34 to 1.99, $P=0.66$).

Conclusions—Pre-ICH statin use is not associated with improved ICH functional outcome or mortality. Post-ICH statin use is not associated with an increased risk of ICH recurrence. (Stroke. 2008;39:2151-2154.)

Key Words: intracerebral hemorrhage ■ outcome ■ statins
not performed or was missing in 46/795 (6%), and other data were missing in 19/795 subjects (3%), leaving 730 subjects with complete baseline information.

Death within 30 days occurred in 251/730, leaving 479/730 30-day survivors. Consenting survivors or a proxy informant (together representing 273/479 of the 30-day survivors, 57%), were interviewed by telephone at 90 days to determine the Glasgow Outcome Scale (GOS) score. To reduce bias we also retrospectively determined GOS at ≥90 days from the medical records of 105/206 nonparticipating ICH survivors. The 101/206 registry subjects without follow-up information had similar baseline characteristics as subjects with follow-up information, except fewer had lobar ICH location (P=0.02). Therefore, in sum, 90-day GOS was determined in a total of 629/730 potential subjects (86%).

Stats and Risk of Recurrence in ICH Survivors
ICH survivors at 90 days were recruited into a prospective longitudinal cohort study designed to find predictors of ICH recurrence. Of 273 eligible survivors, 229 participated (82%). Subjects were followed by telephone every 6 months. Dates of initiation and discontinuation of statins were determined based on subject interview supplemented by available medical records. Dose information was not collected. When the date of statin initiation or discontinuation could not be recalled, it was assigned as the midpoint between successive interviews.

Statistical Analysis
Independent status was defined as GOS 4 or 5. Logistic regression models were constructed to determine whether pre-ICH statin use was associated with independent status or mortality. ICH volume was log-transformed, because of a nonnormal distribution, when analyzed as the dependent variable in multivariable linear regression.

In ICH survivors univariate Cox regression models and Kaplan-Meier plots were used to determine subject characteristics associated with an increased hazard of recurrence. Post-ICH statin use was analyzed as a time-dependent variable because some subjects started or discontinued statins during the follow-up period. Post-ICH statin use and any variables associated with ICH recurrence (P<0.20) were entered into a multivariable Cox regression model, followed by backward elimination of nonsignificant variables (P>0.05). Statistical analyses were performed using SAS version 9.1.3 (SAS Institute, North Carolina).

Results
Pre-ICH Statin Use and ICH Outcome
Pre-ICH statin use was not associated with independent status or mortality (Table 1). Multivariable logistic regression models showed that pre-ICH statin use was not associated with independent status after adjustment for potential confounders (Table 2). Pre-ICH statin use was associated with a nonsignificant 19% increase in ICH volume on admission CT (95% CI −7% to +51%, P=0.16) in a linear regression model controlling for other variables associated with ICH volume (male sex, hypertension, diabetes, previous ICH, and ICH location).

We considered whether the effect of statins use might vary according to outcome definition or patient subgroups. There was no difference in 30-day or 90-day survival in pre-ICH statin users (data not shown). Because statin withdrawal may worsen stroke outcome we performed additional analyses subtracting subjects in whom statins were discontinued (n=22), or adding subjects in whom statins were started (n=25), and found similar results (data not shown). To test for a dose-response effect, those with dose information (105/149, 70%) were dichotomized according to whether the statin dose was ≥50% of the maximum dose recommended by the manufacturer’s labeling. Users of higher-dose statins (n=25), compared to nonusers (n=480), were more likely to have independent status (P=0.78). Finally, we failed to confirm a hypothesis that statins would have a better effect in subjects with higher GCS (GCS >10) or smaller ICH volumes (<30 cm³), tested using interaction terms in the regression models (P>0.50 for both).

Post-ICH Statin Use and Risk of Recurrence in ICH Survivors
Statins were used after ICH discharge in 79/229 (35%) of participating ICH survivors; 57 were discharged on statins and 22 started statins after discharge. Mean follow-up was 1.91±1.58 years, with a total of 437.5 person-years of follow-up and 140.8 person-years of post-ICH statin exposure. Post-ICH statin users were more likely to be older, male, to have been on warfarin before the index ICH, and to have CHD and diabetes (P<0.05 for all comparisons).

Recurrent ICH occurred in 26 subjects (11%). In univariate Cox regression analysis, lobar ICH location and history of additional ICH before the index event were the only predictors of recurrence (P<0.05). Post-ICH statin exposure was not associated with recurrence in univariate Cox regression

Table 1. Baseline Characteristics According to Presence of Statin Use Before ICH

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Statin</th>
<th>No Statin</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>72.4±9.4</td>
<td>71.9±12.7</td>
<td>0.65</td>
</tr>
<tr>
<td>Male</td>
<td>64 (50)</td>
<td>50 (50)</td>
<td>0.005</td>
</tr>
<tr>
<td>Hypertension</td>
<td>89 (75)</td>
<td>75 (75)</td>
<td>0.0003</td>
</tr>
<tr>
<td>CHD</td>
<td>47 (15)</td>
<td>15 (15)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Diabetes</td>
<td>32 (15)</td>
<td>15 (15)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>29 (18)</td>
<td>18 (18)</td>
<td>0.005</td>
</tr>
<tr>
<td>Pre-ICH cognitive impairment</td>
<td>15 (15)</td>
<td>15 (15)</td>
<td>0.99</td>
</tr>
<tr>
<td>Ischemic stroke</td>
<td>23 (14)</td>
<td>14 (14)</td>
<td>0.01</td>
</tr>
<tr>
<td>Previous ICH</td>
<td>9 (6)</td>
<td>6 (6)</td>
<td>0.19</td>
</tr>
<tr>
<td>Warfarin</td>
<td>38 (18)</td>
<td>18 (18)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>GCS</td>
<td>12 (6,15)</td>
<td>12 (6,15)</td>
<td>0.83</td>
</tr>
<tr>
<td>ICH location</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deep hemispheric</td>
<td>44 (48)</td>
<td>48 (48)</td>
<td>0.42*</td>
</tr>
<tr>
<td>Lobar</td>
<td>44 (41)</td>
<td>41 (41)</td>
<td></td>
</tr>
<tr>
<td>Brainstem</td>
<td>2 (4)</td>
<td>4 (4)</td>
<td></td>
</tr>
<tr>
<td>Cerebellum</td>
<td>10 (8)</td>
<td>8 (8)</td>
<td></td>
</tr>
<tr>
<td>ICH volume, cm³</td>
<td>28 (6,51)</td>
<td>22 (8,54)</td>
<td>0.15</td>
</tr>
<tr>
<td>Intraventricular extension</td>
<td>56 (53)</td>
<td>53 (53)</td>
<td>0.64</td>
</tr>
<tr>
<td>90-day independence (GOS 4 or 5)</td>
<td>28 (29)</td>
<td>29 (29)</td>
<td>0.84</td>
</tr>
<tr>
<td>90-day mortality</td>
<td>46 (45)</td>
<td>45 (45)</td>
<td>0.93</td>
</tr>
</tbody>
</table>

Continuous variables displayed as mean±SD, or median (25th percentile, 75th percentile). CHD indicates coronary heart disease; ICH, intracerebral hemorrhage; GCS, Glasgow Coma Scale.

*Chi-square test for distribution of hemorrhages across all locations.
This main limitation of our study is that statin use was not randomly assigned, and therefore associations between statins and either ICH outcome or recurrent ICH may be confounded by other factors associated with statin use, even though we adjusted for recognized confounders using regression models. Our analysis of the dose-response effect of statins on ICH outcome uses the simplistic assumption that maximum dose strengths are equipotent across different drugs.

These data come from a relatively large series of consecutive ICH cases with functional outcome data and prospective follow-up and therefore provide a best estimate of the effect of statins on ICH outcome in the absence of large trials. We calculated that a trial of statins to improve 90-day outcome would need to include 1026 subjects (randomized 1:1 to statin or placebo) to have 90% power to detect an OR $\geq 1.24$, derived from Model C (Table 3), for independent status in the statin arm. Our study suggests that patients already taking statins for prevention of cardiovascular disease may safely continue them during and after ICH. For ICH survivors our data suggest that post-ICH statin exposure is not associated with a large increase in risk of recurrence, at least with the statin types and dosages used in community practice.

### Sources of Funding

Dr Smith is supported by a grant from the National Institute of Neurological Disorders and Stroke (K23 NS046327). Dr Rosand has received research support from the National Institute of Neurological Disorders and Stroke and the American Heart Association. Dr Greenberg has received research support from the National Institute of Neurological Disorders and Stroke and the National Institute of Aging.

### Disclosures

None.

### References


Effect of Statins on Intracerebral Hemorrhage Outcome and Recurrence
Emilie FitzMaurice, Lauren Wendell, Ryan Snider, Kristin Schwab, Rishi Chanderraj, Cathrine Kinnecom, Kaveer Nandigam, Natalia S. Rost, Anand Viswanathan, Jonathan Rosand, Steven M. Greenberg and Eric E. Smith

*Stroke*. 2008;39:2151-2154; originally published online April 24, 2008;
doi: 10.1161/STROKEAHA.107.508861
*Stroke* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/39/7/2151

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Stroke* is online at:
http://stroke.ahajournals.org//subscriptions/